China

target reach ladder climb meet win beat competition
Biotech

InnoCare's TYK2 inhibitor holds its own in ph. 2 psoriasis trial

InnoCare's TYK2 inhibitor has hit the main goals of a phase 2 trial in China, sustaining hopes it can provide a new oral option for patients.
James Waldron Oct 9, 2024 9:10am
Hong Kong

Zephyrm seeks Hong Kong IPO to fund phase 3 cell therapy trials

Oct 2, 2024 8:19am
MA

2 cancer biotechs merge, creating global footprint

Sep 25, 2024 10:54am
Graphic of a puzzle depicting both the US and Chinese flags with missing pieces bridging the two together

Connect reduces China workforce, mulls strategy for asthma drug

Sep 6, 2024 4:37am
china chinese Asia

Allist pays Jacobio $21M, landing role in Chinese KRAS race

Aug 30, 2024 9:12am
Cholesterol

YolTech sells China rights to gene editing therapy for $29M

Aug 27, 2024 10:24am